After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
Hong Kong shareholders have foiled plans by Fosun Pharma to take its biologics subsidiary off the stock market at half the IPO price Key Takeaways: Fosun Pharma has pledged to…
Hengrui Pharma accelerates bid for global brand status
The Chinese drugmaker has outlined plans for a secondary listing in Hong Kong to raise its international profile and bolster its overseas ambitions Key Takeaways: Hengrui Pharmaceuticals started out producing…
InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
Is Fosun Set to Rise Again as China Reopens?
The debt-heavy conglomerate announced a fresh $1 billion in asset sales last week, as growing signs emerge that its looming debt crisis of 2022 may be recedingKey Takeaways:Fosun International announced…
Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely
The Chinese company profited handsomely from its investment in the German vaccine maker, and is most likely selling the stake to help service its parent’s large debtKey Takeaways:Fosun Pharma said…
FAST NEWS: Fosun Pharma’s Revenue Growth Slows Sharply in Third Quarter
The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) said Sunday its revenue increased 1.7% year-on-year to 10.27 billion yuan ($1.4 billion) in the third quarter, as measured using…
FAST NEWS: Fosun Pharma Spends $160 Million on Singapore Cancer Clinic
The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) announced Monday evening it will acquire a 60% stake in Oncocare Medical Pte Ltd, one of the local largest private medical…
Recent Articles
RELATED ARTICLES
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK -
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
2196.HK 600196.SHG
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
